Hem › Melanom › Minnesota › Minneapolis
Kliniska studier för Melanom i Minneapolis, MN
12 studier för Melanom söker deltagare vid platser i och runt Minneapolis (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekryterarObservationsstudieFriska volontärer välkomna
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi bort
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekryterarFas 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi bort
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekryterarFas 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi bort
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RekryterarFas 3
- Allina Health Cancer Institute, Minneapolis
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RekryterarFas 3
- University of Minnesota, Minneapolis
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekryterarFas 1/2
- Minnesota Oncology and Hematology PA, Minneapolis
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RekryterarFas 2
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- och 1 fler
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
Project: Every Child for Younger Patients With Cancer
RekryterarObservationsstudie
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RekryterarFas 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekryterarObservationsstudie
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi bort
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RekryterarFas 3
- University of Minnesota Medical Center, Minneapolis
Melanom-studier i andra städer
- Houston, TX59 studier
- New York City, NY38 studier
- Los Angeles, CA34 studier
- Nashville, TN33 studier
- Pittsburgh, PA31 studier
- Boston, MA26 studier
- Philadelphia, PA23 studier
- San Francisco, CA22 studier
- Atlanta, GA21 studier
- Durham, NC21 studier
- St. Louis, MO21 studier
- Columbus, OH21 studier
Andra studier i Minneapolis
- Bröstcancer27 studier
- Icke-småcellig lungcancer26 studier
- Äggstockscancer24 studier
- Prostatacancer23 studier
- Cancer (alla typer)22 studier
- Hjärtsvikt21 studier
- Lungcancer20 studier
- Akut myeloid leukemi20 studier
- Kolorektal cancer19 studier
- Endometriecancer18 studier
- Parkinsons sjukdom17 studier
- Hjärt-kärlsjukdom15 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.